Home > Publications database > A cost-effectiveness analysis of breast cancer treatment in certified versus non-certified hospitals in Germany. > print

001     310348
005     20260310160406.0
024 7 _ |a 10.1002/ijc.70388
|2 doi
024 7 _ |a pmid:41802986
|2 pmid
024 7 _ |a 0020-7136
|2 ISSN
024 7 _ |a 1097-0215
|2 ISSN
037 _ _ |a DKFZ-2026-00548
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Lwin, Min Wai
|0 P:(DE-He78)cfea723e04704e21f1e1a442c95f25bf
|b 0
|e First author
|u dkfz
245 _ _ |a A cost-effectiveness analysis of breast cancer treatment in certified versus non-certified hospitals in Germany.
260 _ _ |a Bognor Regis
|c 2026
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1773154986_3075691
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:C100#LA:C100# / epub
520 _ _ |a In Germany, the German Cancer Society (Deutsche Krebsgesellschaft [DKG]) accredits hospitals to ensure high-quality cancer treatment through adherence to clinical guidelines and a multidisciplinary approach. Evidence suggests certified hospitals (CHs) achieve better clinical outcomes and prognoses than non-certified hospitals (NCHs). However, additional services required for certification incur substantial, unreimbursed costs, necessitating a focused cost-effectiveness evaluation. This retrospective cohort study utilized anonymized administrative routine healthcare data from Allgemeine Ortskrankenkasse, Germany's largest statutory health insurance. The study sample comprised 143,720 incident breast cancer (BC) patients treated between 2009 and 2017 across both CHs and NCHs. A health system perspective was used in this cost-effectiveness analysis. Direct medical costs (inpatient, outpatient, medication, and certification) were compared between CHs and NCHs. Life-years gained (LYG) were calculated from 5-year restricted mean survival time. The incremental cost-effectiveness ratio (ICER), quantified as cost per LYG, served as the primary outcome measure, reported in 2024 euro. Treatment in CHs significantly improved breast cancer survival, yielding 201 LYG per 1000 patients (95% confidence interval: 185-216). Accounting for €1.5 M in certification-related costs and marginal direct medical costs, the total incremental cost was €1.81 M per 1000 patients. This resulted in an ICER of €9036 per LYG. Despite the financial investment required for DKG certification, BC treatment in CHs provided significant survival benefits at a reasonable incremental cost, reinforcing the clinical and economic value. These findings offer critical insights for hospital authorities and healthcare policymakers, supporting the continued investment in certification.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a breast cancer
|2 Other
650 _ 7 |a breast cancer treatment cost
|2 Other
650 _ 7 |a cancer center certification
|2 Other
650 _ 7 |a certified hospitals
|2 Other
650 _ 7 |a cost‐effectiveness analysis
|2 Other
700 1 _ |a Schoffer, Olaf
|b 1
700 1 _ |a Streissnig, Christoph
|b 2
700 1 _ |a Wimberger, Pauline
|b 3
700 1 _ |a Gerken, Michael
|b 4
700 1 _ |a Bierbaum, Veronika
|b 5
700 1 _ |a Bobeth, Christoph
|b 6
700 1 _ |a Rößler, Martin
|b 7
700 1 _ |a Dröge, Patrik
|b 8
700 1 _ |a Ruhnke, Thomas
|b 9
700 1 _ |a Günster, Christian
|b 10
700 1 _ |a Tol, Kees Kleihues-van
|b 11
700 1 _ |a Link, Theresa
|b 12
700 1 _ |a Scharl, Anton
|b 13
700 1 _ |a Sturm-Inwald, Elisabeth C
|b 14
700 1 _ |a Kast, Karin
|b 15
700 1 _ |a Papathemelis, Thomas
|b 16
700 1 _ |a Ortmann, Olaf
|b 17
700 1 _ |a Klinkhammer-Schalke, Monika
|b 18
700 1 _ |a Schmitt, Jochen
|b 19
700 1 _ |a Schlander, Michael
|0 P:(DE-He78)1f315d09721b91091df1ba78eb65cbaf
|b 20
|e Last author
|u dkfz
773 _ _ |a 10.1002/ijc.70388
|g p. ijc.70388
|0 PERI:(DE-600)1474822-8
|p nn
|t International journal of cancer
|v nn
|y 2026
|x 0020-7136
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)cfea723e04704e21f1e1a442c95f25bf
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-He78)1f315d09721b91091df1ba78eb65cbaf
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2026
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2025-11-11
|w ger
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-11-11
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J CANCER : 2022
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-11-11
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-11-11
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J CANCER : 2022
|d 2025-11-11
920 2 _ |0 I:(DE-He78)C100-20160331
|k C100
|l Gesundheitsökonomie
|x 0
920 1 _ |0 I:(DE-He78)C100-20160331
|k C100
|l Gesundheitsökonomie
|x 0
920 0 _ |0 I:(DE-He78)C100-20160331
|k C100
|l Gesundheitsökonomie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C100-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21